- Conditions
- RSV Infection
- Interventions
- Nirsevimab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 3,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Nirsevimab
- Other
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 0 Days to 12 Months
- Enrollment
- 49,680 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Abrysvo, Beyfortus
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus
- Interventions
- mRNA-1345, mRNA-1365, Placebo, Nimenrix
- Biological · Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 5 Months to 24 Months
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
- Conditions
- Fever, Adverse Event Following Immunisation
- Interventions
- Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Weeks to 30 Weeks
- Enrollment
- 524 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Oakland, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- RSV Infection
- Interventions
- Nirsevimab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 0 Years to 2 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Tampa, Florida • Syracuse, New York + 4 more